Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGALITE: 8 vs 12 Weeks of Elbasvir/Grazoprevir in HCV GT1b
NCT03186365Phase 3Completed
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Start
- Jun 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of grazoprevir in hepatitis C (HCV) (2 arms), sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Primary endpoint: Sustained Virologic Response at 12 Weeks. Started Jun 2017; status: completed.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03186365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03186365.